Evidence map›Paper›PMID 41231231›Full record

Trial reportClinical and translational science2025

Modulating Placebo Effects in Clinical Trials: Study Team Briefing to Optimize Drug-Placebo Differences.

Martin Coenen, Ulrike Bingel, Maria Soledad Berdaguer, Christine Fuhrmann, Robert Németh, Jens Rengelshausen, Gunther Hartmann, Christoph Coch, Manfred Schedlowski

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Martin CoenenClinical Study Core Unit, Study Center Bonn (SZB), University Hospital Bonn, Bonn, Germany.ORCID 0000-0003-0439-4409
Ulrike BingelDepartment of Neurology, Center for Translational Neuro- and Behavioural Sciences, University Hospital Essen, Essen, Germany.ORCID 0000-0002-9528-3204
Maria Soledad BerdaguerClinical Study Core Unit, Study Center Bonn (SZB), University Hospital Bonn, Bonn, Germany.
Christine FuhrmannClinical Study Core Unit, Study Center Bonn (SZB), University Hospital Bonn, Bonn, Germany.ORCID 0009-0004-1527-145X
Robert NémethClinical Study Core Unit, Study Center Bonn (SZB), University Hospital Bonn, Bonn, Germany.
Jens RengelshausenInstitute for Occupational, Social and Environmental Medicine, Uniklinik RWTH Aachen, Aachen, Germany.ORCID 0000-0002-6344-1888
Gunther HartmannInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.ORCID 0000-0003-1021-2018
Christoph CochClinical Study Core Unit, Study Center Bonn (SZB), University Hospital Bonn, Bonn, Germany.ORCID 0000-0002-0815-6750
Manfred SchedlowskiInstitute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro- and Behavioural Sciences, University Hospital Essen, Essen, Germany.ORCID 0000-0002-9968-9770

Funding

Grünenthal GmbH 4500441669
6 · The paper itself

Abstract

Clinical trials often face challenges with placebo effects that can mask actual drug effects. We evaluated whether briefing the study team members on placebo mechanisms influenced analgesia. In this study, we compared the analgesic effects of oxycodone and placebo in three groups of 32 subjects. The groups were treated by an untrained study team (Arm A), a team trained to maximize (Arm B) and a team trained to minimize placebo effects (Arm C). The primary outcome was the reduction of pain during the cold pressor test, assessed by the area under the pain curve of the visual analog scale before and after blinded administration of oxycodone or placebo. Oxycodone and placebo demonstrated the expected differences in pain reduction across all study arms. Briefing the study team did not significantly affect pain reduction or treatment expectation, regardless of treatment. However, treatment expectations were more pronounced with oxycodone compared to placebo, showing a positive correlation of expectation and treatment effect only in the oxycodone group, possibly reflecting the influence of unblinding due to adverse effects. These findings suggest that a brief training of the study team may not be sufficient to alter treatment expectations and placebo analgesia. This insight will inform future efforts to apply placebo research to optimize blinded trial design and drug treatments in clinical settings. Trial Registration: DRKS 00013586 (German Clinical Trials Register), registered on December, 22nd 2017; URL: https://www.drks.de/drks_web/setLocale_EN.do.

Indexed as

Analgesics, OpioidOxycodonePainPlacebo EffectAdultDouble-Blind MethodFemaleHumansMalePain MeasurementPlacebosTreatment OutcomeYoung AdultAnalgesics, OpioidOxycodonePlacebosanalgesic therapyplacebo effectplacebo responsestudy team

Identifiers

PMID41231231
PMCPMC12614085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.